Search results for: Precision Medicine
Filter search results
Medicines for the year 2000
1 September 1979
…profitably say a few words about the pharmaceutical industry in Britain at the present time. On reflection this is by no means inappropriate to a consideration of medicines for the…
Medicines: 50 Years of Progress 1930-1980
7 January 1980
…limits of space and time which have constrained our text in two main aspects. First, we have chronicled the development of new medicines by way of groupings related to the…
Spotlight on OHE: Assessing Value and Balancing Needs in Health Care
15 December 2011
…students at City University London on current issues in valuing health and international research on them. Containing spending on medicines and ensuring access Policies intended to contain and shape spending…
Recent Statistics on Orphan Approvals in Scotland and England
23 August 2011
In October 2009, the OHE published research that compared access to orphan medicinal products (OMPs) in selected European countries. At the request of the UK Orphan Medicines Industry Group [1],…
Drug shortages are on the rise – but what is their impact?
16 September 2024
…AAM, 2022. Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report | Association for Accessible Medicines. [online] Available at: https://accessiblemeds.org/resources/reports/2022-savings-report [Accessed 10 Sep. 2024]. ASPE, 2023. ASPE Report to Congress: Impact of…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…medicines increased after the 2010 introduction of the Cancer Drugs Fund even in the face of unfavourable NICE recommendations. The value of a particular medicine, as this study illustrates well,…
Spotlight on OHE: Innovation, Regulation and Antibiotics
30 September 2014
…of goods and services. The source of the regulatory problem for prescription medicines in the NHS is that the consumer (patient) neither decides which medicine is prescribed nor is responsible…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
…indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
The notion that the price of a medicine should be linked in some way to value it generates for patients and the health system is generally accepted. Yet, how can…